Plain-English translation of NCT06141031 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Pancreatic Cancer research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two treatments for pancreatic cancer: radiation therapy (given over 3 weeks) plus an experimental oral medication called (taken by mouth twice daily). The idea is that may help the radiation work better and reduce harmful side effects while boosting your immune system's ability to fight the cancer.
Pancreatic cancer has a very poor survival rate, and radiation therapy alone, while helpful, hasn't improved how long patients survive. Laboratory research suggests that this medication could work together with radiation to enhance these benefits and help more patients avoid cancer progression.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you qualify, you will take the medication by mouth twice daily while receiving radiation therapy over 3 weeks (5 treatment sessions). After that, if your cancer is borderline resectable and becomes resectable, you may have surgery; if not, you'll continue the medication alone for up to 10 weeks, with a biopsy around weeks 9โ13 to assess your response. Your doctor will also monitor your health throughout with blood tests and imaging. After the study treatment ends, you'll receive standard chemotherapy as part of your regular cancer care.
AI-generated summary from trial data ยท Oct 2, 2026 ยท Not medical advice
United States